Geron Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp.

GERN 1.145

-5.0%

Nov 4 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: seminole	12/10/2013 9:43:51 AM
	of 3576

Geron upgraded to Buy at Needham; tgt $10; Imetelstat data at ASH exceeds expectations8:44 AM ET, 12/10/2013 - Briefing.com . Needham upgrades GERN to Buy from Hold and sets tgt at $10. Last night Geron presented updated data from an ongoing investigator-sponsored Phase II study of imetelstat in myelofibrosis (MF) patients at the American Society for Hematology (ASH). GERN shares have run ahead of the data from this open label study based on upbeat commentary from the company and earlier positive data in essential thrombocytopenia. While firm has advised caution ahead of a peer-reviewed release of the MF data, it can now report that the robustness of these data exceed its expectations

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next